Metraipolis › archive › dc_d37841fea840

Ocrelizumab in early relapsing-remitting multiple sclerosis: first interim analysis of the MUSPO Italian prospective cohort — Europe PMC PMID:42126632

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42126632
DOI
10.1007/s00415-[numero omesso]-0
License (as archived)
solo-consultazione
Archived
2026-11-02T17:45:13.398Z
SHA-256 of the archived text
49008ea9c67574eb037def0d6e29b80025ed38f9ae62ad8cadf72c210485b35a
Stable URL of this page
https://metraipolis.com/documento/dc_d37841fea840

How to cite

Ocrelizumab in early relapsing-remitting multiple sclerosis: first interim analysis of the MUSPO Italian prospective cohort — Europe PMC PMID:42126632 — Europe PMC (en), https://europepmc.org/article/MED/42126632 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_d37841fea840 (Metraipolis archive dc_d37841fea840, sha256 49008ea9c67574eb037def0d6e29b80025ed38f9ae62ad8cadf72c210485b35a)
BibTeX
@misc{dcd37841fea840,
  title = {Ocrelizumab in early relapsing-remitting multiple sclerosis: first interim analysis of the MUSPO Italian prospective cohort — Europe PMC PMID:42126632},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42126632},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_d37841fea840; sha256 49008ea9c67574eb037def0d6e29b80025ed38f9ae62ad8cadf72c210485b35a},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42126632. Agents can read the archived copy with the MCP tool read_document.